Aetion, a NYC-based software platform company delivering real-world analytics and evidence to biopharma and payers, raised $36.4m in Series B funding.
The round was led by New Enterprise Associates (NEA) with participation fro new investor Amgen Ventures and existing investors Flare Capital Partners, Lakestar, and Oxeon Ventures. In conjunction with the funding, Mohamad Makhzoumi of NEA will join the Aetion board of directors.
The company, which has raised a total of $50m to date, intends to use the funds to further build out its platform to support specific complex therapeutic areas and expand its team of biopharma and pharmacy benefit design experts.
Led by Carolyn Magill, chief executive officer, Aetion provides a software solution which leverages data to evaluate the safety, effectiveness, and value of medications. Biopharma companies can use the platform to demonstrate to payers and regulators which medications will best serve their populations – supporting care access and appropriateness. For payers, it provides the ability to identify therapies that are both clinically effective and cost-effective – enabling formulary and plan design that boost patient outcomes and curb premium hikes.